U.S. Markets open in 6 hrs 2 mins

INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc.


Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acorda Therapeutics, Inc. (“Acorda” or the “Company”) (ACOR).

If you purchased or otherwise acquired Acorda shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.

You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation focuses on whether Acorda and certain of its officers and/or directors violated federal securities laws. On August 29, 2017, the Company announced that it received a Refusal to File letter from the U.S. Food & Drug Administration (the “FDA”) regarding its New Drug Application for Inbrija. Specifically, the FDA determined that the New Drug Application was not complete enough to permit a substantive review. The FDA cited two specific issues: the date the manufacturing site would be ready for inspection; and a question regarding the submission of the drug master production record. The FDA has also requested further information at resubmission, which did not form the basis for the Refusal to File. Following this news, Acorda’s stock price dropped.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170908005744/en/